DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Santen Pharmaceutical
Santen Pharmaceutical
Santen Reports Consolidated Results for Q2 Fiscal 2019 | Santenusa.Com
Expanding the European Business and Accelerating Growth Making a Positive Contribution As a Specialized Ophthalmic Pharmaceutical Company
Guidelines with Regard to the Composition, Calculation and Management of the Index
President and CEO's
Medium-Term Plan "MTP2025"
Annual Report 2018
Santen and Merck & Co., Inc Sign Licensing Agreement for Tafluprost
Biopharma Expansion to China and Asia
Data Book Half Year Ended September 30, 2016
Consolidated Financial Results for Year Ended March 31, 2020
Notice of Commencement of Preparation for Transition to a Holding Company Structure Through Sole-Share Transfer and Change in Fiscal Year
Year Ended March 31, 2010
Research & Development
President and CEO's Message
Eyeing Further Year Ended March 31, 2013 Specialization CONTENTS
2005 Form 10-K
FY2020 Financial Results
Ar2016e 02.Pdf
Top View
Year Ended March 31, 2019
News Release
GLOBAL SMALL COMPANIES EQUITY First Quarter 2021 Report
Corporate Presentation Santen EMEA
Corporate Report 2018
Corporate Information / Stock Information 77 3 01 T 2 S Epor F N R T
Annual Report 2019
Summary of Consolidated Financial Results for the Year Ended March 31, 2021 (IFRS)
UNITED STATES SECURITIES and EXCHANGE COMMISSION Washington, D.C
130-Year History Our Value Creation
Japan and Asia Business Update
Feature Contributing to Further Enhance Ophthalmic Treatment in Asia
Corporate Information / Stock Information / Stock Information Corporate Business Bases As of August 2012
Corporate Information / Stock Information As of March 31, 2016
Happiness with Vision CORE PRINCIPLE
Business Review Japan Business
Corporate Information / Stock Information As of March 31, 2015
Research & Development